Author

Samantha B. Kemp

University of PennsylvaniaORCID 0000-0002-1505-4015Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:imaging· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Ben Z. StangeriD· 2 shared Cynthia J. ClendeniniD· 2 shared Margo OrleniD· 2 shared A. Cole EdwardsiD· 1 shared Álvaro Curiel‐GarcíaiD· 1 shared Amanda R. Decker-FarrelliD· 1 shared Amber M. AmparoiD· 1 shared Andrea CalifanoiD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ben Z. StangerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyCancer Research CommunicationsPeer-reviewedSep 17, 2025

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types

Zahra Davoudi, Thomas Steven Dexheimer, Nathan P. Coussens…·Beverly A. Teicher

This study screens combinations of RAS pathway inhibitors with targeted agents in patient-derived spheroids with KRAS variants, identifying effective combinations that reduce viability.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyClinical Cancer ResearchPeer-reviewedApr 21, 2025

Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy

Mamta Gupta, Hoon Choi, Samantha B. Kemp…·Rong Zhou

7 citations

mouseimaging

𝕏 PostBluesky

Cancer BiologyNaturePeer-reviewedApr 8, 2024

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton…·Kenneth P. Olive

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

225 citationstop 1%

humanmouse

𝕏 PostBluesky